
Moleculin Biotech (MBRX) Stock Forecast & Price Target
Moleculin Biotech (MBRX) Analyst Ratings
Based on 4 analyst ratings
Strong Buy
Strong Buy 75%
Buy 25%
Hold 0%
Sell 0%
Strong Sell 0%
Moleculin Biotech (MBRX) has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 75% of analysts recommend a Strong Buy, 25% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.
This aggregate rating is based on analysts' research of Moleculin Biotech and is not a guaranteed prediction by Public.com or investment advice.
This aggregate rating is based on analysts' research of Moleculin Biotech and is not a guaranteed prediction by Public.com or investment advice.
Moleculin Biotech (MBRX) Analyst Forecast & Price Prediction
Get the latest Moleculin Biotech (MBRX) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis
Start investing in Moleculin Biotech (MBRX)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Moleculin Biotech (MBRX) Forecast
Analysts have given Moleculin Biotech (MBRX) a Strong Buy based on their latest research and market trends.
According to 4 analysts, Moleculin Biotech (MBRX) has a Strong Buy consensus rating as of Jun 16, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.
Wall Street analysts have set a price target of $13.25, reflecting a 0.00% increase from the current stock price.
Financial analysts have set a price target of $13.25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.